⌕
Telix Pharmaceuticals · TLX · Nasdaq
Tenet 41 · Weak
Compare
$8.86−0.73%At closeTenet 41 · Weak
$8.86−0.07 (−0.73%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Telix Pharmaceuticals (TLX) Stock

Telix Pharmaceuticals (TLX) closed at $8.86 on Nov 17, 2026; its Tenet Score is 41 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

41 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$8.86
Nov 17, 2026
52-week range
6.28 – 13.11
low → high · as of close, Nov 16, 2026
Tenet Score
41/100
Weak · 340 Healthcare peers

Industry: Pharmaceutical Preparations

Telix Pharmaceuticals Ltd. scores 41/100. Weak. Financial health is the soft spot versus 340 Healthcare peers. Insufficient inputs: Tenet 41 is built from 3 of 4 pillars, from 40% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=340
41/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
—
Quality
44
Health
20
Growth
59

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Value omitted — no data yet.
Value—QualityDHealthFGrowthCMomentumC
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
—
Withheld: the figures this depends on are not on the same share, currency or period basis.
P/S
—
Withheld: the figures this depends on are not on the same share, currency or period basis.
ROE
−4%
fiscal year to Dec 31, 2025
Operating margin
−0.6%
before interest and tax
Net margin
−1.9%
fiscal year to Dec 31, 2025
Current ratio
1.43
fiscal year to Dec 31, 2025
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Market cap
—
no market cap on file
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Telix Pharmaceuticals Ltd.

We are a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. Our mission is to be the global leader in radiopharmaceuticals by combining therapeutic and diagnostic m…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 3 US ETFs · top wrappers by weightSee all ETFs holding TLX →

What sector and industry is Telix Pharmaceuticals in?

Telix Pharmaceuticals is in the Healthcare sector and the Pharmaceutical Preparations industry.

What is Telix Pharmaceuticals' Tenet Score?

Telix Pharmaceuticals' Tenet Score is 41 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.